Beta Bionics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Beta Bionics, Inc. (BBNX) on March 27, 2025, reporting events occurring on March 26, 2025. The Company is an emerging growth company incorporated in Delaware, with principal executive offices in Irvine, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation.
Material Changes
The primary material change reported is the appointment of Gerard Michelas as a Class III director of the Company, effective March 26, 2025. His term expires at the 2028 annual meeting of stockholders. No other material financial or operational changes were disclosed in this filing.
Management Commentary, Risks, and Compensation
Mr. Michelas brings significant experience as a former CEO of Delcath Systems, Inc., and former CFO of Vericel Corporation, Biodel, Inc., and NPS Pharmaceuticals, Inc. His appointment was recommended by the Nominating and Corporate Governance Committee. There are no arrangements or understandings between Mr. Michelas and any other person regarding his selection, nor are there any transactions requiring disclosure under Item 404(a) of Regulation S-K.
Compensation arrangements for Mr. Michelas include:
- Annual Cash Retainer: $50,000 for service on the Board.
- Initial Equity Grant: 12,547 restricted stock units (RSUs) granted on the date of appointment, vesting in full on the one-year anniversary, subject to continuous service.
- Future Equity Grants: Automatic grants of RSUs with an aggregate grant date value of $165,000 on the date of each annual meeting of stockholders, vesting on the one-year anniversary or the day preceding the next annual meeting.
- Change in Control: All RSU grants vest in full upon a change in control.
Mr. Michelas has also entered into the Company's standard form of Indemnification Agreement.
Investor Verification Checklist
- Verify the impact of the new director's background on the Company's strategic direction in interventional oncology and biopharmaceuticals.
- Confirm the total number of authorized shares under the 2025 Equity Incentive Plan to assess dilution from the 12,547 RSUs and future automatic grants.
- Review the Company's upcoming 10-Q or 10-K filings for the most recent financial performance data, as this 8-K contains no financial metrics.
- Monitor the vesting schedule of the RSUs to understand future compensation expenses.